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BACKGROUND: The clinical features of invasive lobular carcinoma (ILC) of the breast have remained
unclear due to the rarity of such cases. This study investigated the clinical and pathological features 
of ILC.
METHODS: The medical records of 413 patients with invasive breast cancer who underwent surgery in
our department were reviewed. These cases included 13 patients with ILC (3.1%).
RESULTS: The age of the patients ranged from 36 to 77 years old (mean, 56). The tumour size was evalu-
ated as T1 in five patients, T2–4 in 8. The lymph node metastasis was diagnosed as negative in six patients,
positive in six. In this patient population, 11 (85%) and nine (69%) patients were positive for oestrogen
and progesterone receptors, respectively. The 5-year survival rate was 76.2%, which was not significantly
different from other types of invasive breast cancer. Extensive intraperitoneal metastasis was observed in
two of the three patients. Two patients had bilateral carcinoma and one patient had a multicentric lesion
in the ipsilateral breast.
CONCLUSION: Multicentric development of breast cancer and intraperitoneal metastasis were one of
clinical characteristics of ILC. The prognosis of ILC was not significantly different from other types of
invasive breast carcinoma. [Asian J Surg 2009;32(2):76–80]
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Introduction
Breast cancer is the one of leading causes of cancer death
among women in industrialized countries.1 In 1941,
Stewart et al. proposed the entity of lobular carcinoma as
a type of breast cancer.2 They described both an invasive
form and an in situ form of the disease which was confined
to the lobule and terminal ducts.3 Invasive lobular carci-
noma (ILC) is the second most common type of invasive
breast cancer after invasive ductal carcinoma, and accounts
for 5–15% of all breast cancer in Europe and the United
States, respectively.4,5 The incidence of invasive lobular
carcinoma in Japan was approximately 1–4% among all
breast cancer.6,7 A recent epidemic study indicated that
the incidence of this type of breast cancer is increasing,
especially among postmenopausal women.6 Reports indi-
cated that the use of combined oestrogen and proges-
terone hormone replacement therapy increased the risk of
all types of breast cancer, especially ILC.5
Because ILC lesions are less common and include sev-
eral subtypes such as, classic, alveolar, solid, tubulo-lobular,
signet ring cell and pleomorphic subtypes,8 it is some-
what difficult to describe the clinical characteristics cate-
gorically. However, some of the clinical features have been
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reported to be (1) multicentric development in the same
or the adjacent breast in greater proportions than other
types of breast cancer, (2) ill-defined margins and subtle
thickening or indurations observed in mammography
(finding of architectural distortion), (3) more frequent
expression of oestrogen receptors (ER) and (4) gastroin-
testinal and peritoneal metastasis.6,8–10 Although there
are several differences in the clinicopathological charac-
teristics of ILC and invasive ductal carcinoma, both types
of carcinoma are usually managed using the same clinical
strategy. In this study, the clinical and pathological char-
acteristics of patients with invasive lobular carcinoma
who underwent surgery in this department were reviewed.
Patients and methods
The clinical and pathological features of 413 patients
with invasive breast cancer who underwent a surgical
resection in this department between 1981 and 2005 were
observed. The patients’ records were retrieved and the
clinical data, preoperative examination results, details of
the surgical procedure, histopathological findings, and
TNM stages of all patients were reviewed. All patients had
received a physical examination, ultrasonography of the
breast, and mammography during the preoperative eval-
uation. The assessments for distant metastasis included
chest roentgenography, computed tomography (CT) of
the chest and upper abdomen, and bone scintigraphy. All
resected specimens, including the primary tumour and
resected regional lymph nodes were examined for tumour
histology and the extent of lymph node metastases. The
histopathological findings were classified according to
the General Rules for Clinical and Pathological Recording
of Breast Cancer 2005.11 ER and progesterone receptor
(PgR) in the cancer tissues were measured by an enzyme
immunoassay, or immunohistochemical staining of sec-
tions taken from formalin-fixed, paraffin-embedded
blocks of the surgical specimens. The cancer tissues were
available in 312 patients (75.5%) for evaluation of hor-
mone receptors. Follow-up information was obtained
from all patients through office visits or telephone inter-
views with either the patient, a relative, or their primary
physicians. The mean observation time was 4.6 years.
Categorical variables were compared by Fisher’s exact
test for proportion. The survival curve was calculated by
the Kaplan-Meier method, and compared by using the
Log-rank test for univariate analysis. Differences were
considered to be significant, if the p value was less than
0.05. The Statview V software program (Abacus Concept,
Berkeley, CA) was used for all statistical analyses.
Results
The average age of the patients was 56.3 years (range,
36–77 years) and 53.5 (range, 23–97 years old) in the
patients with ILC and other types of invasive breast can-
cer, respectively. The subjects included 13 patients with
ILC (3.1%) among the 413 patients with invasive breast
cancer. They consisted of five premenopausal and eight
postmenopausal women. The tumour size of the ILC was
evaluated as T1 in five patients, T2 in six, T3 in one and
T4 in one (Table 1). The proportion of T1 tumours was
similar to that of other types of invasive breast cancer. The
lymph node metastasis of the ILC patients was diagnosed
pathologically as N0 in six patients, N1 in four, N2 in two,
and N3 in one. The percentage of lymph node metastasis
tended to be higher than that of other types of invasive
breast cancer, but no statistical significant difference was
observed. The surgical procedure used for patients with
ILC included Bt + Ax in six patients, Bt + Ax + Ic in two,
Bt + Ax + Ic + Mn in two, Bt in two and Bt + Ax + Ic + Mn +
Mj in one. In these cases, 11 (85%) and nine (69%) patients
with ILC were positive for ER and PgR, respectively.
Adjuvant chemotherapy was administered in 10 patients
based on the following regimen; CAF (cyclophosphamide +
adriamycin + fluorouracil) in five, AC (cyclophosphamide +
adriamycin) followed by paclitaxel in three, 5DFUR 
(5-deoxy-5-fluorouridine) in two patients. Endocrine ther-
apy with tamoxifen was combined in three patients, and
aromatase inhibitor was administrated in two. An oopho-
rectomy was performed in two patients in the 1980s. The
5-year survival rate was 76.2%, which was not significantly
different from that of patients with other types of invasive
breast cancer (Figure 1). In two of the three patients who
died, extensive intraperitoneal metastases were detected. Two
patients had bilateral lobular carcinoma (one synchronous
and one metachronous) and one patient had a multicen-
tric lesion in the ipsilateral breast.
Discussion
ILC develops from the acinar epithelium of the mammary
gland and frequently invades the normal tissues without
involvement of the abundant desmoplastic response that
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usually accompanies invasive ductal carcinoma.2,3 Focal
masses are not always obvious clinical features, but they
are sometimes difficult to distinguish from dense normal
parenchyma.4 More than one third of mammograms of
these lesions reveal vague asymmetries, poorly defined
opacities, or architectural distortions.8 Microcalcifica-
tions are frequent manifestations of ductal carcinomas,
but are uncommon in ILC.12 Using sonography, ILC
appears as a heterogeneous, hypoechoic mass with ill-
defined margins and a posterior acoustic shadow.13 Selinko
et al reported that sonography had a greater sensitivity
than mammography for the detection of ILC and had the
advantage of evaluating the presence of the axillary lymph
node metastasis.14 However, the sensitivity in the detec-
tion of ILC has varied according to the investigations,
ranging from 57–81% for mammography and 68–87% for
sonography.13,15 Enhanced magnetic resonance (MR)
imaging of the breast is extremely sensitive for the detec-
tion of ILC and is also useful to evaluate the extent of the
disease.16 Rodenko et al reported that the extent of dis-
ease determined by pathological examination correlated
well with the prediction based on MR imaging.17 The ill-
defined margins are probably related to the pathological
findings that ILC spreads through the breast parenchyma
with diffuse infiltration of single rows of malignant cells
in a linear fashion surrounding the non neoplastic ducts
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Figure 1. Overall survival curves of the patients with breast 
cancer. The 5-year survival rate of patients with invasive lobular
carcinoma was 76.2% which was not significantly different from
that of patients with other types of invasive breast cancer.
Table 1. Comparison of the pathological characteristics between invasive lobular carcinoma and other types of invasive breast 
cancers
Invasive lobular carcinoma Other types of invasive breast cancer 
Characteristics (n= 13) (n= 400)
Number of patients (%) Number of patients (%)
T categories
T1 5 (38.5) 168 (42.0)
T2 6 (46.2) 172 (43.0)
T3 1 (7.7) 51 (12.8)
T4 1 (7.7) 9 (2.3)
N categories
N0 6 (46.2) 241 (61.5)
N1 4 (30.8) 117 (29.8)
N2 2 (15.4) 26 (6.6)
N3 1 (7.7) 8 (2.0)
M categories
M0 10 (76.9) 386 (96.5)
M1 3 (23.1) 14 (3.5)
Oestrogen receptor status
Positive 11 (84.6) 199 (63.8)
Negative 2 (15.4) 113 (36.2)
Progesterone receptor status
Positive 9 (69.2) 165 (52.9)
Negative 4 (30.8) 147 (47.1)
and that this infiltration causes little disruption of the
underlying anatomical structures and generates only a
slight surrounding connective tissue reaction.18
Because of the infiltrative growth pattern and frequent
discontinuity (multicentric development) that is observed
in ILC, there has been a tendency to treat patients with more
aggressive surgery, including mastectomy and standard
axillary lymph node dissection. The rate of local recur-
rence after conservative surgery and radiation therapy is
high because of the frequent incidence of multicentricity
and bilateral occurrence.19,20 The rate of positive margin
in the breast conservation therapy for ILC is reported to
be over 50% and it is more frequent than that observed in
invasive ductal carcinoma.21–23 In the present study, none
of the patients underwent breast conservation therapy. 
Vo et al reported the result of with breast conservation
therapy (BCT) and radiation in 84 patients with ILC and
1,126 with invasive ductal carcinoma with stage I or II 
disease. In their study, the 10-year local-regional recurrence
rates for the ILC group and invasive ductal carcinoma
group were 7% and 9%, respectively, indicating no signifi-
cant differences between the two groups.24 Therefore,
breast conservation treatment is now being increasingly
used for invasive lobular carcinoma, yielding outcomes
equivalent to those of more aggressive surgical treat-
ment.25,26 Santiago et al also reported that similar long-
term results for breast conservation treatment for invasive
lobular carcinoma to that observed with invasive ductal
carcinoma.27 Therefore, we considered that breast conser-
vation treatment should have been tried for patients 
at stage I (T1) in this study. The response to primary
chemotherapy for ILC is lower than invasive ductal carci-
noma; therefore systemic therapy should be restricted to
patients with inoperable or recurrent ILC.28 Although
adjuvant chemotherapy in breast cancer patients present-
ing with lymph nodal involvement is a standard option
currently, it is necessary to consider a prospective random-
ized trial to evaluate the role of adjuvant chemotherapy
versus hormonal therapy in ILC patients.29
The tumour diameter observed in ILC is reported to
be slightly larger in comparison to other types of invasive
breast cancer.10 However the proportion of T1 was simi-
lar to other invasive carcinomas in this study. The inci-
dence of lymph node metastasis with ILC tended to be
higher (53.8%) than that of other types of invasive breast
cancer (38.5%) in this study, but the difference was not
statistically significant. The proportion of lymph node
metastasis of ILC is reported to occur at the same rate in
comparison to other types of invasive breast cancer.10 ER
expression was reported to reveal more frequently in ILC
than other types of invasive breast cancer.30 In the cases
reviewed in this study, 85% of the ILC patients were posi-
tive for ER which was a higher ratio than other types of
invasive breast cancer.
The pattern of distant metastasis in ILC was different
from invasive ductal cancer of the breast. Lung and pleura
involvement was more frequently observed with invasive
ductal carcinoma, as was involvement of the distant lymph
nodes and of the central nervous system. The metastasis
of the gastrointestinal tract, gynaecologic organs or the
peritoneum is rare in invasive ductal carcinoma. On the
other hand, ILC often metastasizes to the intraperitoneal
organs (through haematogenous metastasis and peri-
toneal dissemination), suggesting that this type of metas-
tasis is one of the specific features of ILC.31–33 Metastasis
of ILC origin in the intraperitoneal organs frequently
shows a signet ring cell appearance and the loss of expres-
sion of membrane E-cadherine.34 In this study, two patients
died due to extensive intraperitoneal metastasis (mural
haematogenous metastases of gastrointestinal tract). 
In spite of these clinicopathological differences, the prog-
nosis of ILC shows no difference in comparison with
other types of invasive breast cancer.10,30
The multicentric development of the ipsilateral or bilat-
eral breast is another clinical feature of ILC. Bilateral
involvement is reported to be 20–29% in ILC, which is an
extremely high frequency as compared with that of invasive
ductal carcinoma.19,20,35 This finding suggests that careful
follow-up is necessary for development of a metachronous
contralateral carcinoma after surgery. This study included
two patients with bilateral lobular carcinoma of the breast.
One patient presented with synchronous cancer and the
other patients was diagnosed with a contralateral bilateral
lobular carcinoma 5 years after initial operation.
In conclusion, there are several clinicopathological
characteristics of ILC, however, the prognosis of ILC is
not significantly different from other types of invasive
breast carcinoma and therefore no differences in the 
therapeutic management are considered to be necessary.
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